Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: rationale and general considerations

Iorio, Alfonso, Edginton, Andrea N., Blanchette, Victor, Blatny, Jan, Boban, Ana, Cnossen, Marjon, Collins, Peter ORCID: https://orcid.org/0000-0002-6410-1324, Croteau, Stacy E., Fischer, Katheljin, Hart, Daniel P., Ito, Shinya, Korth-Bradley, Joan, Lethagen, Stefan, Lillicrap, David, Makris, Mike, Mathôt, Ron, Morfini, Massimo, Neufeld, Ellis J. and Spears, Jeffrey 2018. Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: rationale and general considerations. Research and Practice in Thrombosis and Haemostasis 2 (3) , pp. 535-548. 10.1002/rth2.12106

Preview

PDF - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (796kB) | Preview

Abstract

Objectives In a separate document, we have provided specific guidance on performing individual pharmacokinetic (PK) studies using limited samples in persons with hemophilia with the goal to optimize prophylaxis with clotting factor concentrates. This paper, intended for clinicians, aims to describe how to interpret and apply PK properties obtained in persons with hemophilia. Methods The members of the Working Party on population PK (PopPK) of the ISTH SSC Subcommittee on Factor VIII and IX and rare bleeding disorders, together with additional hemophilia and PK experts, completed a survey and ranking exercise whereby key areas of interest in the field were identified. The group had regular web conferences to refine the manuscript’s scope and structure, taking into account comments from the external feedback to the earlier document. Results Many clinical decisions in hemophilia are based on some form of explicit or implicit PK assessment. Individual patient PK profiles can be analyzed through traditional or PopPK methods, with the latter providing the advantage of fewer samples needing to be collected on any prophylaxis regimen, and without the need the for a washout period. The most useful presentation of PK results for clinical decision making are a curve of the factor activity level over time, the time to achieve a certain activity level, or related parameters like half‐life or exposure (AUC). Software platforms have been developed to deliver this information to clinicians at the point of care. Key characteristics of studies measuring average PK parameters were reviewed, outlining what makes a credible head‐to‐head comparison among different concentrates. Large data collections of PK and treatment outcomes currently ongoing will advance care in the future. Conclusions Traditionally used to compare different concentrates, PK can support tailoring of hemophilia treatment by individual profiling, which is greatly simplified by adopting a PopPK/Bayesian method and limited sampling protocol.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	Wiley
ISSN:	2475-0379
Date of First Compliant Deposit:	22 May 2018
Date of Acceptance:	9 April 2018
Last Modified:	05 May 2023 01:09
URI:	https://orca.cardiff.ac.uk/id/eprint/111620

Citation Data

Cited 52 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item